This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

2014 FDA Drug Approval Calendar

Stocks in this article: OMER BDSI KERX OREX NPSP GILD CELG BIIB CBST MNKD EXAS

NEW YORK (TheStreet) -- It's been awhile since I updated the FDA drug approval calendar. Here's the latest list of drugs under FDA review. Included as well are relevant FDA advisory panel dates. 

Enjoy.

May 2014:

Biogen Idec  (BIIB)
Plegridy for multiple sclerosis
May 21

Eli Lilly  (LLY)and Dyax (DYAX)
Ramucirumab for gastric cancer
May 23

Durata Therapeutics (DRTX) 
Dalbavancin for skin infections
May 26
(An FDA advisory panel in March voted to recommend approval.)

Omeros (OMER)
OMS302 for ocular inflammation
May 30


June 2014: 

BioDelivery Sciences  (BDSI)
Bunavail for opioid addiction
June 6

Exact Sciences (EXAS)
Cologuard for colon cancer screening
June 6 

Keryx Pharmaceuticals  (KERX)
Zerenex for hyperphosphatemia (kidney dialysis)
June 6

Orexigen Therapeutics (OREX)
Contrave for obesity
June 10 

June 11-12
FDA advisory committee meeting to discuss treatments for opioid-induced constipation
AstraZeneca (AZN) and Nektar Therapeutics (NKTR) - naloxogel
Salix Pharma (SLXP) -- Relistor

Biogen Idec 
Eloctate for hemophilia A
June 12

Cubist Pharma  (CBST)
Tedizolid for skin infections
June 20

July 2014: 

MannKind  (MNKD)
Afrezza for diabetes
July 15

July 24
FDA advisory panel
NPS Pharmaceuticals (NPSP)
Natpara for hypoparathyroidism July 24

Anacor Pharma
  (ANAC)
Tavaborole for toe fungus
July 29


August 2014: 

Medicines Co. (MDCO)
Oritavancin for skin infections (MRSA)
Aug. 6

Spectrum Pharmaceuticals (SPPI)
Belinostat for peripheral T-cell lymphoma
Aug. 8

Regeneron Pharmaceuticals (REGN)
Eylea for diabetic macular edema (expansion of label)
Aug. 18


September 2014: 

Gilead Sciences (GILD)
Idelalisib for indolent non-Hodgkin's lymphoma 
Sept. 11 (pending FDA acceptance of priority review)

AstraZeneca and Nektar Therapeutics
Naloxegol for opioid-induced constipation
Sept. 16

Celgene (CELG)
Otezla for psoriasis (expansion of label)
Sept. 23


October 2014: 

NPS Pharmaceuticals  (NPSP)
Natpara for hypoparathyroidism
Oct. 24

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs